SML3476
Brivaracetam
≥98% (HPLC)
别名:
(αS,4R)-α-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide, (2S)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide, (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, UCB 34714, UCB-34714, UCB34714
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C11H20N2O2
化学文摘社编号:
分子量:
212.29
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
assay
≥98% (HPLC)
form
powder
drug control
USDEA Schedule V
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Brivaracetam shows approximately 10 times greater potency than levetiracetam (Keppra)*; pIC50 at LBS = 7.0; inhibits audiogenic seizures in seizure-prone mice (ED50 = 14 μmol/kg) and is also effective in other animal models of epilepsy. Brivaracetam is used as an anticonvulsant (antiepileptic) for seizure treatment.
Orally active levetiracetam analog with higher synaptic vesicle protein 2A (SV2A) affinity and >10 times greater in vivo antiseizure efficay.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus
Journal of neural transmission (Vienna, Austria : 1996), 114(12), 1547-1551 (2007)
Brivaracetam attenuates pain behaviors in a murine model of neuropathic pain
Molecular Pain (2019)
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity
Journal of medicinal chemistry, 47(3), 530-549 (2004)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持